A recent study published in Quaternary Research describes the discovery and identification of possible aardvark tracks and ...

We recently published a list of Top 10 Insider Purchases Last Month. In this article, we are going to take a look at where ...

Morgan Stanley started coverage on shares of Aardvark Therapeutics (NASDAQ:AARD – Free Report) in a research note released on Monday morning, MarketBeat.com reports. The brokerage issued an overweight ...

Cantor Fitzgerald assumed coverage on shares of Aardvark Therapeutics (NASDAQ:AARD – Free Report) in a report issued on Monday morning, Marketbeat reports. The brokerage issued an overweight rating ...

RBC Capital analyst Brian Abrahams initiated coverage of Aardvark Therapeutics (AARD) with an Outperform rating and $21 price target Aardvark ...

BofA initiated coverage of Aardvark Therapeutics (AARD) with a Buy rating and $22 price target The company’s lead drug ARD-101 is in Phase 3 ...

In this article, we are going to take a look at where Aardvark Therapeutics, Inc. (NASDAQ:AARD) stands against other stocks with at least $10 million in insider spending recently. Since Donald ...

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...